NCT07219940View on ClinicalTrials.gov

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Healthy SubjectsExosomeTargeted Therapy
Interventions
DRUG

SOB100

Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.

Trial Locations (1)

21225

Parexel International - Baltimore Early Phase Clinical Unit, Baltimore

All Listed Sponsors
lead

Shine-On Biomedical Co., Ltd.

INDUSTRY

NCT07219940 - A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects | Biotech Hunter | Biotech Hunter